quetiapine / Generic mfg. - LARVOL DELTA

Cross national pharmacovigilance analysis of drug-induced delirium: a comparative study using the US FAERS, Japanese JADER, and canadian CVAR datasets. (PubMed, Front Pharmacol) - "Duloxetine, lamotrigine, pregabalin, quetiapine fumarate, and zolpidem demonstrated consistent signals across databases. Time-to-onset analysis demonstrated early-onset clustering, suggesting an acute temporal pattern. Cross-database consistency in drug class signals and early-onset temporal patterns highlights the need for medication review and risk mitigation in high-risk populations."

Adverse events • Journal • CNS Disorders • Cognitive Disorders • Pain

Potentially inappropriate medications in older outpatients with depression: a cross-sectional study comparing the Beers criteria and the Chinese criteria. (PubMed, Front Psychiatry) - "Under both criteria, quetiapine, benzodiazepines and sedative-hypnotics were the most frequently identified as PIMs...The single-center retrospective design, unmeasured confounders, unavailability of renal function data, and lack of follow-up assessment warrant cautious interpretation of the results. Multidisciplinary medication review and individualized deprescribing strategies can be implemented in clinical practice for this vulnerable population."

Journal • Observational data • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Heart Failure • Ischemic stroke • Mood Disorders • Psychiatry • Sleep Disorder

IV LIPID EMULSION AS RESCUE THERAPY IN A PATIENT WITH QUETIAPINE TOXICITY (CHEST 2026) - No abstract available

Clinical • Critical care

Depression in Parkinson's Disease: Real-World Prescribing Patterns and Treatment Dynamics from a Nationwide Greek Cohort. (PubMed, Mov Disord Clin Pract) - "In PD depression, AAP outlast SSRIs in real-world persistence and non-SSRIs are more commonly switched or augmented."

Journal • Real-world evidence • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

A Long-Term, Open-Label, Study on Schizophrenia (clinicaltrials.gov) - P2/3 | N=560 | Terminated | Sponsor: Denovo Biopharma LLC | N=1210 ➔ 560

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia

How Often Do QT-prolonging Drugs Really Prolong QT? A Systematic Review. (PubMed, J Psychiatr Pract) - "Drug-induced QTc prolongation is not uncommon across a range of widely used medications, especially in psychiatric care, yet its monitoring and risk remain inconsistently assessed, particularly in outpatient settings. While TdP was rarely reported, QTc >500 ms occurred with notable frequency. Significant heterogeneity in QTc definitions, study populations, and ECG methodologies limits cross-study comparability, underscoring the need for greater standardization."

Journal • Review • Cardiovascular • CNS Disorders • Psychiatry

Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report. (PubMed, Clin Park Relat Disord) - "He was referred specifically for a trial of clozapine therapy, which the patient and caregiver declined due to its risk profile. The patient's psychosis proved refractory to three pharmacologically distinct therapies-quetiapine, a low-affinity, rapidly dissociating dopamine D2 receptor antagonist; brexpiprazole, a dopamine D2 partial agonist; and pimavanserin, a selective 5-HT2A receptor inverse agonist-before improving with xanomeline-trospium, whose antipsychotic effects are mediated through central M1/M4 muscarinic receptor agonism. This case supports the further investigation of muscarinic receptor agonism as a therapeutic strategy for Parkinson's disease psychosis."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • DRD2

Treatment of Parkinson's Disease-Related Psychosis. (PubMed, Clin Pharmacol) - "When antipsychotic therapy is required, pimavanserin and clozapine demonstrate the strongest evidence for efficacy...Quetiapine is widely used despite inconsistent evidence from randomized trials, largely due to its favorable safety profile and ease of use...Current therapeutic strategies allow symptom control in many patients, yet important gaps in the evidence base persist, particularly regarding long-term outcomes. Future research should prioritize mechanistically informed therapies, standardized outcome measures, and the identification of predictors of treatment response."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Diagnosis of Antipsychotic Medication-Induced Severe Hypertriglyceridaemia by the Phenomenon of Pseudohyponatraemia and Successful Management With Variable-Rate Intravenous Insulin Infusion: A Case Report. (PubMed, Case Rep Endocrinol) - "Acute pancreatitis did not develop during the inpatient admission or during outpatient follow-up, and triglyceride levels have fallen substantially (3.2 mmol/L at 5 months) having been switched from quetiapine and risperidone to aripiprazole, an SGA associated with less metabolic disturbance. This case demonstrates the safe and effective management of SGA-associated severe HTG with intravenous insulin infusion to prevent acute pancreatitis. It also highlights the utility of pseudohyponatraemia as a useful way of detecting severe HTG and the impact of SGA medications in the aetiology of severe HTG."

Journal • CNS Disorders • Diabetes • Dyslipidemia • Mental Retardation • Metabolic Disorders • Pancreatitis • Psychiatry • Severe Hypertriglyceridemia

Update on Parkinson's Disease Psychosis: Epidemiology, Mechanisms and Management. (PubMed, Neurol Ther) - "Pimavanserin and clozapine are the only pharmacologic therapies for PDP that have been found to be efficacious in randomized controlled trials, though quetiapine is most frequently used despite lacking positive trial results. Future research that continues to clarify the exact pathophysiology of psychosis in PD will improve the current therapeutic approaches, and ongoing randomized clinical trials of these therapies are necessary to identify the safest and most efficacious treatments for PD patients with psychosis."

Clinical • Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Sex-specific pharmacovigilance signals and time-to-onset patterns of drug-related myoclonus and epileptic seizures: a real-world pharmacovigilance analysis. (PubMed, Front Pharmacol) - "Bupropion had the highest report count (1,412; 265 myoclonus and 1,147 epileptic seizure reports), followed by tramadol (829). For myoclonus, gabapentin showed strong signals in males (ROR = 23.31, 95% CI: 20.95-25.95) and females (ROR = 18.06, 95% CI: 16.24-20.08), whereas tranexamic acid showed the strongest male signal (ROR = 128.41, 95% CI: 98.29-167.75)...CVARD identified 498 myoclonus-related and 940 seizure-related drugs and reproduced core signals, including clozapine, gabapentin, baclofen, pregabalin, sertraline, bupropion, quetiapine, and olanzapine. Integrating signal detection, sex-stratified analysis, TTO modeling, and cross-database validation identified core risk drugs and monitoring windows, supporting earlier recognition and individualized management of drug-related neurological adverse events."

Adverse events • Journal • Real-world evidence • Cardiovascular • CNS Disorders • Epilepsy • Metabolic Disorders • Mood Disorders • Movement Disorders • Oncology

A 6-Year-Old With Becker Muscular Dystrophy and Catatonia. (PubMed, Pediatrics) - "He received many medication treatments for catatonia, including escalating doses of lorazepam and augmentation with memantine, zolpidem, quetiapine, and ultimately clozapine, without adequate symptom improvement and with side effects including significant weight gain. This case highlights the importance of the identification of catatonia to guide evidence-based treatment and the value of timely access to electroconvulsive therapy for pediatric patients. While the etiology of his catatonia remains undetermined, his diagnosis of BMD could play a role and further supports the importance of a comprehensive medical work-up."

Journal • Becker Muscular Dystrophy • CNS Disorders • Duchenne Muscular Dystrophy • Immunology • Muscular Dystrophy • Pediatrics • Psychiatry

A case report: Neuropsychiatric presentation of atypical Rasmussen's encephalitis. (PubMed, S Afr J Psychiatr) - "Interventions required a multidisciplinary team, and pharmacological management included sodium valproate and lamotrigine for seizure control, as well as quetiapine and fluoxetine for behavioural disturbances. Late diagnosis may have contributed to the patient's poor prognosis. Despite the need for further research, early neuroimaging of patients with new adult-onset seizures may help decrease morbidity associated with RE."

Journal • CNS Disorders • Cognitive Disorders • Developmental Disorders • Epilepsy • Psychiatry

Association of common QT-prolonging medications with arrhythmic risk in patients with bundle branch block: A stratified cohort analysis in left bundle branch block vs. right bundle branch block phenotypes. (PubMed, Heart Lung) - "Common non-cardiac QT-prolonging medications were not associated with increased risk in patients with BBB, even with prolonged QTc. The divergence between composite and sensitivity results for amiodarone highlights the influence of confounding by indication. Medication alerts should incorporate stratification by drug class rather than QTc alone."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Critical care • Heart Failure

The Effect of Psychotropic Agents on Sick Sinus Syndrome: A Case Report. (PubMed, Cureus) - "A review of her regimen identified several cardiac safety concerns: quetiapine's potential interference with flecainide, hydroxyzine-associated QT prolongation, and bupropion's CYP2D6 inhibition that could increase flecainide levels. Management prioritized minimizing arrhythmogenic risk by discontinuing quetiapine, restricting hydroxyzine to low doses, and continuing melatonin, supplemented by stress testing and reassessment of psychotropic options. This case highlights the importance of careful psychotropic selection in patients with SSS, favoring lower-risk agents, such as mirtazapine, which is one of the safest among several possible alternatives, while maintaining close ECG monitoring and coordinated cardiology and psychiatry collaboration to reduce drug-drug interactions and optimize safety."

Journal • Cardiovascular • CNS Disorders • General Anxiety Disorder • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder • Ventricular Tachycardia

Interim data from ENIGMA – TRS 1 study of evenamide as add on therapy to antipsychotic Standard of Care in patients with treatment resistant schizophrenia (TRS). Difficulties in performing TRS study with TRRIP criteria: the CRO experience (WFSBP 2026) - "One aspect of the ENIGMA – TRS 1 study assesses plasma concentrations of standard of care as selected antipsychotics: Aripiprazole, Brexpiprazole, Cariprazine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone and Ziprasidone for subjects treated with those antipsychotics with daily therapeutic doses meeting local product labels requirements and correlated those with minimal duration of 6 weeks treatment with any of those medications. As the study is performed in 20 countries worldwide major issues reside in getting approval by all regulatory approvals, languages use for the rating instruments as well as for the training of the raters. Based on hundreds of patients entering screening, a large proportion failed the screening phase because of lack of adequate concentration of the primary AP. Difficulties have been noticed in ensuring adequate documentation of previous AP failures."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Effect of levodopa-carbidopa intestinal gel infusion on objective measures of daytime sleepiness and nocturnal sleep in Parkinson's disease. (PubMed, Rev Neurol (Paris)) - "LCIGI had no significant impact on objectively measured daytime sleepiness (MSLT) or PSG sleep parameters."

Journal • CNS Disorders • Excessive Daytime Sleepiness • Movement Disorders • Parkinson's Disease • Sleep Disorder

Risk assessment of infections and infestations associated with second-generation antipsychotics: A comprehensive analysis of the FAERS database. (PubMed, Schizophr Res) - "Through real‑world pharmacovigilance analysis, aspiration pneumonia associated with SGAs was identified as the most prominent p‑IIAE. The present findings are anticipated to offer valuable information to support the safe and rational use of SGAs in patients."

Journal • CNS Disorders • Infectious Disease • Pneumonia • Respiratory Diseases

Pancreaticobiliary Mimicker: Double Duct Sign Without Obstruction? (ACG 2026) - "Quetiapine dose reduction and initiation of metoclopramide resulted in rapid symptomatic improvement. AJR Am J Roentgenol. 1986 Oct;147(4):729-31 Figure: EGD showing a large amount of food residue in gastric fundus, and ampulla appeared to be normal Figure: Upper EUS showing dilated common bile duct of 7.5mm and dilated main pancreatic duct of 4.3mm, and smooth tapering of both ducts into the ampulla."

Biliary Cancer • Cardiovascular • CNS Disorders • Congestive Heart Failure • Diabetes • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hepatology • Metabolic Disorders • Pulmonary Disease • Schizophrenia • Type 2 Diabetes Mellitus

Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in Portugal. (PubMed, Front Psychiatry) - "TRD treatments initiated at baseline were varied; the most common treatments initiated or ongoing at baseline were mirtazapine (43.1%), venlafaxine (42.5%), quetiapine (25.5%), and trazodone (20.9%). Outcomes for patients with TRD in real-world clinical practice remain poor, with most patients not responding after 20 weeks of treatment. Treatment heterogeneity highlights a lack of clinical consensus, and the need for novel therapeutics and improved treatment protocols for TRD in real-world clinical practice in Portugal."

Clinical • Journal • Observational data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

PAB-2202-001: An Intravenous versus Oral Crossover study to assess safety, bioavailability and pharmacokinetics of investigational product RLS-2202 in healthy adults compared to oral Seroquel (ANZCTR) - P1 | N=16 | Not yet recruiting | Sponsor: Patrys Ltd

New P1 trial • CNS Disorders

Detected Delirium Prevalence and Practices in Australia and New Zealand: A Sub-Analysis of the World Delirium Awareness Day Prevalence Study. (PubMed, Australas J Ageing) - "In Australia and New Zealand, delirium assessment practices have improved over time. Non-pharmacological strategies are widely used; however, antipsychotic use remains substantial. Workforce constraints, education gaps and system pressures may contribute to variability in delirium care delivery. Addressing these factors, alongside engagement with carers, may support further improvements in care. Ongoing surveillance through repeated surveys would help monitor trends in delirium care over time."

Journal • CNS Disorders • Pain

S-38 Oligodendroglia as treatment target in schizophrenia (WFSBP 2026) - "Quetiapine is known to enhance myelination in the frontal cortex and other brain areas, which translates into improved cognition. Compared with schizophrenia patients not treated with the drug, quetiapine-treated patients showed significant improvement in working memory and verbal learning and memory cognitive domains."

Alzheimer's Disease • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

Myelin-related drugs to treat cognitive deficits in schizophrenia (WFSBP 2026) - "In the multicenter PsyCourse study in 212 patients with SZ we found that quetiapine-treated patients showed significant improvement in prefrontal (working memory) and temporal (verbal learning and memory) cognitive domains compared with SZ patients not treated with the drug. These clinical trials might lead to a new, mechanistically informed pharmacological treatment for cognitive dysfunction in SZ and generate biomarkers to identify the patients who benefit most from this strategy. Our studies support an oligodendrocyte pathology in schizophrenia and suggest that reducing functional dysconnectivity reflect a potential therapeutic target to improve cognitive impairments."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Mental Retardation • Psychiatry • Schizophrenia

Catatonia with prominent psychosocial factors: A case report. (PubMed, PCN Rep) - "In this patient, catatonia showed dose-dependent re-emergence during tapering of both lorazepam and quetiapine, with remission on re-escalation. Even when psychosocial factors appear prominent, careful monitoring and gradual dose adjustment may be important for maintaining remission."

Journal • CNS Disorders • Psychiatry • Psychosomatic Disorders • Schizophrenia